Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 334.5 EUR -0.74% Market Closed
Market Cap: 2.8B EUR
Have any thoughts about
Virbac SA?
Write Note

Intrinsic Value

The intrinsic value of one VIRP stock under the Base Case scenario is 377.15 EUR. Compared to the current market price of 334.5 EUR, Virbac SA is Undervalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VIRP Intrinsic Value
377.15 EUR
Undervaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Virbac SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VIRP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VIRP?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Virbac SA

Provide an overview of the primary business activities
of Virbac SA.

What unique competitive advantages
does Virbac SA hold over its rivals?

What risks and challenges
does Virbac SA face in the near future?

Has there been any significant insider trading activity
in Virbac SA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Virbac SA.

Provide P/S
for Virbac SA.

Provide P/E
for Virbac SA.

Provide P/OCF
for Virbac SA.

Provide P/FCFE
for Virbac SA.

Provide P/B
for Virbac SA.

Provide EV/S
for Virbac SA.

Provide EV/GP
for Virbac SA.

Provide EV/EBITDA
for Virbac SA.

Provide EV/EBIT
for Virbac SA.

Provide EV/OCF
for Virbac SA.

Provide EV/FCFF
for Virbac SA.

Provide EV/IC
for Virbac SA.

Show me price targets
for Virbac SA made by professional analysts.

What are the Revenue projections
for Virbac SA?

How accurate were the past Revenue estimates
for Virbac SA?

What are the Net Income projections
for Virbac SA?

How accurate were the past Net Income estimates
for Virbac SA?

What are the EPS projections
for Virbac SA?

How accurate were the past EPS estimates
for Virbac SA?

What are the EBIT projections
for Virbac SA?

How accurate were the past EBIT estimates
for Virbac SA?

Compare the revenue forecasts
for Virbac SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Virbac SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Virbac SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Virbac SA compared to its peers.

Compare the P/E ratios
of Virbac SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Virbac SA with its peers.

Analyze the financial leverage
of Virbac SA compared to its main competitors.

Show all profitability ratios
for Virbac SA.

Provide ROE
for Virbac SA.

Provide ROA
for Virbac SA.

Provide ROIC
for Virbac SA.

Provide ROCE
for Virbac SA.

Provide Gross Margin
for Virbac SA.

Provide Operating Margin
for Virbac SA.

Provide Net Margin
for Virbac SA.

Provide FCF Margin
for Virbac SA.

Show all solvency ratios
for Virbac SA.

Provide D/E Ratio
for Virbac SA.

Provide D/A Ratio
for Virbac SA.

Provide Interest Coverage Ratio
for Virbac SA.

Provide Altman Z-Score Ratio
for Virbac SA.

Provide Quick Ratio
for Virbac SA.

Provide Current Ratio
for Virbac SA.

Provide Cash Ratio
for Virbac SA.

What is the historical Revenue growth
over the last 5 years for Virbac SA?

What is the historical Net Income growth
over the last 5 years for Virbac SA?

What is the current Free Cash Flow
of Virbac SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Virbac SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Virbac SA

Current Assets 877.3m
Cash & Short-Term Investments 156.9m
Receivables 295.8m
Other Current Assets 424.7m
Non-Current Assets 918.9m
Long-Term Investments 5.2m
PP&E 381.1m
Intangibles 499.4m
Other Non-Current Assets 33.2m
Current Liabilities 530.6m
Accounts Payable 149.8m
Accrued Liabilities 57.6m
Short-Term Debt 4m
Other Current Liabilities 319.3m
Non-Current Liabilities 271.4m
Long-Term Debt 209.2m
Other Non-Current Liabilities 62.2m
Efficiency

Earnings Waterfall
Virbac SA

Revenue
1.3B EUR
Cost of Revenue
-450.3m EUR
Gross Profit
889.1m EUR
Operating Expenses
-665.3m EUR
Operating Income
223.8m EUR
Other Expenses
-82.9m EUR
Net Income
140.9m EUR

Free Cash Flow Analysis
Virbac SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VIRP Profitability Score
Profitability Due Diligence

Virbac SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Free Cash Flow
Positive 3-Years Revenue Growth
57/100
Profitability
Score

Virbac SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

VIRP Solvency Score
Solvency Due Diligence

Virbac SA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
78/100
Solvency
Score

Virbac SA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VIRP Price Targets Summary
Virbac SA

Wall Street analysts forecast VIRP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VIRP is 412.6 EUR with a low forecast of 378.75 EUR and a high forecast of 453.18 EUR.

Lowest
Price Target
378.75 EUR
13% Upside
Average
Price Target
412.6 EUR
23% Upside
Highest
Price Target
453.18 EUR
35% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VIRP?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for VIRP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VIRP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Virbac SA Logo
Virbac SA

Country

France

Industry

Pharmaceuticals

Market Cap

2.8B EUR

Dividend Yield

0.39%

Description

Virbac SA engages in the manufacture and sale of veterinary medicines. The company is headquartered in Carros, Paca. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. The company also offers food and electronic identification chips for pets.

Contact

PACA
Carros
13eme rue LID, Bp 27, Carros Cedex
+33492087100.0
corporate.virbac.com

IPO

1985-01-01

Employees

4 907

Officers

Interim CEO & CFO
Mr. Habib Ramdani
Deputy CEO and Head of Compliance & Corporate Quality Assurance
Mr. Marc Bistuer
Head of Corporate Communications
Ms. Sandrine Brunel
Head of Global Marketing & Market Development
Ms. Nathalie Pollet
Head of Corporate Human Resources
Ms. Francesca Cortella
Head of Global Business Operations
Ms. Sophie Favini
Show More
Head of Corporate R&D
Mr. Bertrand Havrileck
Head of Global Industrial Operations, Supply Chain and Sourcing
Mr. André Mathieu
Director of Financial Projects
Manuela RodrĂ­guez
Show Less

See Also

Discover More
What is the Intrinsic Value of one VIRP stock?

The intrinsic value of one VIRP stock under the Base Case scenario is 377.15 EUR.

Is VIRP stock undervalued or overvalued?

Compared to the current market price of 334.5 EUR, Virbac SA is Undervalued by 11%.

Back to Top